Results 1 to 10 of about 279,740 (162)
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Frontiers in Immunology, 2022 Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies.
Xiaomin Zhang +6 more
doaj +3 more sources
CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments
Frontiers in Immunology, 2022 Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell leukemia or lymphoma. Unfortunately, many challenges remain to be addressed
Manasi P. Jogalekar +7 more
doaj +3 more sources
CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
Frontiers in ImmunologyChimeric Antigen Receptor (CAR)-T cell therapy has rapidly emerged as a groundbreaking approach in cancer treatment, particularly for hematologic malignancies. However, the application of CAR-T cell therapy in solid tumors remains challenging.
Yaojie Kong +4 more
doaj +3 more sources
Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy
Acta Pharmaceutica Sinica BChimeric antigen receptor T (CAR-T) cell therapy as a form of adoptive cell therapy (ACT) has shown significant promise in cancer treatment, demonstrated by the FDA-approved CAR-T cell therapies targeting CD19 or B cell maturation antigen (BCMA) for ...
Dian Xiong, Haijun Yu, Zhi-Jun Sun
doaj +3 more sources
Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions
Cells, 2023 T cells expressing chimeric antigen receptors (CARs) are at the forefront of clinical treatment of cancers. Still, the nanoscale organization of CARs at the interface of CAR-Ts with target cells, which is essential for TCR-mediated T cell activation ...
Julia Sajman +7 more
doaj +1 more source
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
Frontiers in Immunology, 2023 Over the last decade, the survival outcome of patients with multiple myeloma (MM) has been substantially improved with the emergence of novel therapeutic agents, such as proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies ...
Xiaomin Zhang +4 more
doaj +1 more source
Immunological Medicine, 2021 Chimeric antigen receptor (CAR) is generated by fusing a cancer-specific antibody’s antigen recognition site with costimulatory molecules such as CD28 and CD3ζ. T cells transduced with CAR recognizes cancer-specific antigens and kill cancer cells.
Naoki Hosen
doaj +1 more source
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Biomarker Research, 2021 B-cell non-Hodgkin lymphoma (B-NHL) is a group of heterogeneous disease which remains incurable despite developments of standard chemotherapy regimens and new therapeutic agents in decades.
Zixun Yin, Ya Zhang, Xin Wang
doaj +1 more source
Hematology/Oncology and Stem Cell Therapy, 2022 Chimeric antigen receptor T-cell (CAR T-cell) therapy represents an innovative and transformative therapy for patients with relapsed and/or refractory (R/R) hematological malignancies.
Farah Yassine +4 more
doaj +1 more source
Frontiers in Oncology, 2021 CAR T-cell therapy has revolutionized the treatment approach to patients with relapsed/refractory hematologic malignancies; however, there continues to be opportunity for improvement in treatment toxicity as well as response durability. Radiation therapy
Penny Q. Fang +7 more
doaj +1 more source